Beta-catenin signaling in endothelial cells during cerebral malaria

脑型疟疾期间内皮细胞中的β-连环蛋白信号传导

基本信息

  • 批准号:
    9017351
  • 负责人:
  • 金额:
    $ 50.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-15 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Cerebral malaria (CM) is caused by the interaction between Plasmodium falciparum infected erythrocytes (iRBC) and host brain endothelial cells. While available anti-malarial drugs are effective at clearing parasites from the blood, they do not have specific effects against cerebral malaria. Using an in vitro model, we have found that P. falciparum-iRBC induce the activation of β-catenin in human brain microvascular endothelial cells (HBMEC), which results in their detachment from the substrate and disruption of inter-endothelial cell junctions. The activation of β-catenin induces transcription of Tcf/LEF in the nucleus of HBMEC, which mediates the disruptions induced by P. falciparum-iRBC. We observed that treatments that inhibit the activation of β-catenin, result in protection against P. falciparum-induced damage in endothelial cell monolayers in vitro and against experimental CM in mice. We propose that β-catenin activation in brain endothelium is a central event in the development of CM pathology and that its inhibition can be explored for adjunct treatment against cerebral malaria. We have identified that the signaling induced by angiotensin II receptors (AT1 and AT2) modulates β-catenin in endothelial cells and, as a result, the integrity of the inter-endothelial junctions and blood brain barrier integrity. Modulators of these receptors some of which are already approved or in clinical trials for use in humans, protect mice from experimental CM even when treatment is started after severe neurological symptoms are present. We intend to identify the P. falciparum-induced signaling pathway in endothelial cells leading to activation of β- catenin and its inhibition by the AT2 signaling cascade to evaluate th importance of these pathways in human disease. Using a three-pronged approach with human brain microvascular endothelial cells in vitro, mouse models for cerebral malaria and endothelial cells from cerebral malaria patients, we intend to determine the role of these signaling pathways in human cerebral malaria. Our main goal is to understand P. falciparum- induced signaling in endothelial cells leading to the disruption of the blood brain barrier during cerebral malaria to develop therapies that, by inhibiting these signaling pathways, will specifically protect against cerebral malaria pathology. These findings may be relevant to the treatment of other brain hemorrhagic diseases, since more robust inter- endothelial junctions will result in a stronger blood brain barrier that would limit hemorrhagic pathology.
 描述(由申请人提供):脑型疟疾(CM)是由恶性疟原虫感染的红细胞(iRBC)和宿主脑内皮细胞之间的相互作用引起的。虽然现有的抗疟疾药物在清除血液中的寄生虫方面是有效的, 对脑型疟疾有特效使用体外模型,我们发现恶性疟原虫-iRBC诱导人脑微血管内皮细胞(HBMEC)中β-连环蛋白的活化,这导致它们从基底上脱离并破坏内皮细胞间连接。β-catenin的激活诱导HBMEC核中Tcf/LEF的转录,其介导恶性疟原虫-iRBC诱导的破坏。我们观察到,抑制β-连环蛋白活化的治疗导致对P. 恶性疟原虫诱导的体外内皮细胞单层损伤和小鼠实验CM。我们认为脑内皮细胞中β-连环蛋白的激活是CM病理学发展的中心事件,并且可以探索其抑制以辅助治疗脑型疟疾。我们已经确定,血管紧张素II受体(AT 1和AT 2)诱导的信号传导调节内皮细胞中的β-连环蛋白,从而调节内皮细胞间连接的完整性和血脑屏障的完整性。这些受体的调节剂,其中一些已经被批准或在临床试验中用于人类,保护小鼠免受实验性CM,即使在严重的神经症状出现后开始治疗。我们打算鉴定恶性疟原虫诱导的内皮细胞中导致β- catenin活化的信号通路及其通过AT 2信号级联的抑制,以评估这些通路在人类疾病中的重要性。使用三管齐下的方法与人脑微血管内皮细胞在体外,脑型疟疾的小鼠模型和脑型疟疾患者的内皮细胞,我们打算确定这些信号通路在人脑型疟疾中的作用。我们的主要目标是了解恶性疟原虫诱导的内皮细胞信号传导,导致脑型疟疾期间血脑屏障的破坏,以开发通过抑制这些信号传导途径,将特异性保护脑型疟疾病理的疗法。这些发现可能与其他脑出血性疾病的治疗相关,因为更稳健的内皮间连接将导致更强的血脑屏障,这将限制出血性病理学。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edward A Fisher其他文献

Technology Insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging
技术洞察:利用磁共振成像靶向生物分子以评估高危动脉粥样硬化斑块
  • DOI:
    10.1038/ncpcardio0013
  • 发表时间:
    2004-11-01
  • 期刊:
  • 影响因子:
    44.200
  • 作者:
    Michael J Lipinski;Valentin Fuster;Edward A Fisher;Zahi A Fayad
  • 通讯作者:
    Zahi A Fayad
Summing up
加起来
  • DOI:
    10.1007/bf00871232
  • 发表时间:
    1947
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Edward A Fisher
  • 通讯作者:
    Edward A Fisher
Rapid regression of atherosclerosis: insights from the clinical and experimental literature
动脉粥样硬化的快速消退:来自临床和实验文献的见解
  • DOI:
    10.1038/ncpcardio1086
  • 发表时间:
    2008-02-01
  • 期刊:
  • 影响因子:
    44.200
  • 作者:
    Kevin Jon Williams;Jonathan E Feig;Edward A Fisher
  • 通讯作者:
    Edward A Fisher

Edward A Fisher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edward A Fisher', 18)}}的其他基金

Novel regulatory mechanisms controlling hepatic apoB-Lp lipid loading and secretion
控制肝脏apoB-Lp脂质负荷和分泌的新调控机制
  • 批准号:
    10628991
  • 财政年份:
    2023
  • 资助金额:
    $ 50.56万
  • 项目类别:
Atherosclerosis core
动脉粥样硬化核心
  • 批准号:
    10628989
  • 财政年份:
    2023
  • 资助金额:
    $ 50.56万
  • 项目类别:
Administrative, Biostatistics, Data Management, and Bioinformatics Core
行政、生物统计学、数据管理和生物信息学核心
  • 批准号:
    10616527
  • 财政年份:
    2017
  • 资助金额:
    $ 50.56万
  • 项目类别:
Administrative, Biostatistics, Data Management, and Bioinformatics Core
行政、生物统计学、数据管理和生物信息学核心
  • 批准号:
    10424901
  • 财政年份:
    2017
  • 资助金额:
    $ 50.56万
  • 项目类别:
Macrophage Dysfunction in Obesity, Diabetes and Atherosclerosis
肥胖、糖尿病和动脉粥样硬化中的巨噬细胞功能障碍
  • 批准号:
    9209582
  • 财政年份:
    2017
  • 资助金额:
    $ 50.56万
  • 项目类别:
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin Resistance
解决动脉粥样硬化斑块和胰岛素抵抗其他部位的巨噬细胞炎症
  • 批准号:
    10424904
  • 财政年份:
    2017
  • 资助金额:
    $ 50.56万
  • 项目类别:
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
动脉粥样硬化和心脏代谢疾病中的巨噬细胞功能障碍
  • 批准号:
    10616525
  • 财政年份:
    2017
  • 资助金额:
    $ 50.56万
  • 项目类别:
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
动脉粥样硬化和心脏代谢疾病中的巨噬细胞功能障碍
  • 批准号:
    10424900
  • 财政年份:
    2017
  • 资助金额:
    $ 50.56万
  • 项目类别:
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin Resistance
解决动脉粥样硬化斑块和胰岛素抵抗其他部位的巨噬细胞炎症
  • 批准号:
    10616536
  • 财政年份:
    2017
  • 资助金额:
    $ 50.56万
  • 项目类别:
Macrophage Dysfunction in Obesity, Diabetes and Atherosclerosis
肥胖、糖尿病和动脉粥样硬化中的巨噬细胞功能障碍
  • 批准号:
    9925242
  • 财政年份:
    2017
  • 资助金额:
    $ 50.56万
  • 项目类别:

相似海外基金

Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
  • 批准号:
    493141
  • 财政年份:
    2023
  • 资助金额:
    $ 50.56万
  • 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
  • 批准号:
    10734120
  • 财政年份:
    2023
  • 资助金额:
    $ 50.56万
  • 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
  • 批准号:
    445961
  • 财政年份:
    2021
  • 资助金额:
    $ 50.56万
  • 项目类别:
    Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
  • 批准号:
    19K17401
  • 财政年份:
    2019
  • 资助金额:
    $ 50.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
  • 批准号:
    411570
  • 财政年份:
    2019
  • 资助金额:
    $ 50.56万
  • 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
  • 批准号:
    391615
  • 财政年份:
    2018
  • 资助金额:
    $ 50.56万
  • 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
  • 批准号:
    26460229
  • 财政年份:
    2014
  • 资助金额:
    $ 50.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
  • 批准号:
    25870715
  • 财政年份:
    2013
  • 资助金额:
    $ 50.56万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
  • 批准号:
    8531707
  • 财政年份:
    2012
  • 资助金额:
    $ 50.56万
  • 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
  • 批准号:
    8397394
  • 财政年份:
    2012
  • 资助金额:
    $ 50.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了